Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...

The MOCA Geffen is spotlighting two major crowd-pullers: Olafur Eliasson ’s seductive light installation OPEN, on view ...

Aharon, Ph.D., Co-Founder & CEO of AEYE Health, in conversation with Jake Laznik, Senior Breaking News Desk Manager, The ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta ...

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...

JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...

JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...

(RTTNews) - Alpha Tau Medical Ltd. (DRTS), an Israeli oncology therapeutics company, on Monday announced promising interim data from multiple clinical trials involving its Alpha DaRT therapy.